Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 1 - 10 of 243
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Development Phase: Discovery and Early Development
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development

Pages

Displaying 11 - 20 of 70
Alternative Name: ATPase Plasma Membrane Calcium Transporting 4, PMCA4, Plasma Membrane Calcium-Transporting ATPase 4, PMCA4b, PMCA4x, Matrix-Remodeling-Associated Protein 1, Sarcolemmal Calcium Pump, EC 7.2.2.10, EC 3.6.3.8, EC 3.6.3
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification

Pages

Displaying 71 - 80 of 121
Alternative Name: Nestorone (NES) Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
Alternative Name: Nestorone + Testosterone Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Development Stage: Phase II
Alternative Name: Nestorone (NES) Metered Dose Transdermal System® (MDTS®)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Acrux, Ltd., Fempharm Pty Ltd.
Development Stage: Phase I
Alternative Name: Nestorone (NES) + Estradiol (E2) Transdermal Gel
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Antares, Population Council
Development Stage: Phase II
Alternative Name: Biodegradable Norethindrone (NET) Pellets
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Anterion Therapeutics, FHI 360
Development Stage: Phase II
Alternative Name: Non-Invasive Laser Male Sterilization
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Vas Deferens
Developer: University of North Carolina at Charlotte
Development Stage: Pre-clinical
Alternative Name: Oil-based drospirenone (DSRP) microcrystal suspension
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Male
Hormonal: No
Delivery Method: Oral
Developer: South African Medical Research Council, University of Western Cape
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: ZK 98.299; ZK 98 299
User: Female
Hormonal: Yes
Developer: Schering AG
Development Stage: Pre-clinical

Pages

Displaying 11 - 20 of 52
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Oral
Developer: HRA Pharma
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Alternative Name: ENG + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Amneal
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited, Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST)
Development Stage: Marketed
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed

Pages

CSV